Overview

A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Status:
Recruiting

Trial end date:
2023-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the target dose of phase II and to evaluate the safety, tolerability, pharmacokinetics and efficacy of recombinant anti-IL-1β humanized monoclonal antibody injection at different doses in Chinese participants with acute gout.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Treatments:

Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Betamethasone
Immunoglobulins